Pancreatic Location, High Proliferation and Low p-mTOR Expression Levels Are More Frequent in Neuroendocrine Tumor Patients Responsive to mTOR Inhibitors: Results from a Preliminary Study

#1221

Introduction: MTOR inhibitors are approved for the treatment of advanced neuroendocrine tumors. However, scarce data are available on clinical or pathological predictors of response to these agents

Aim(s): To test in a pilot series the presence of clinical and pathological predictors of response to mTOR inhibitors.

Materials and methods: Clinical and pathological characteristics (sex, age, location of the primary tumor, tumor grade and Ki-67 index) and the expression of phosphorylated forms of mTOR and p70S6K were correlated with response to therapy in 20 neuroendocrine tumor patients treated with everolimus

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Volante M

Authors: Birocco N, Brizzi M, Airoldi M, De Angelis C, Ciuffreda L,

Keywords: mTOR inhibitor, biomarker,